Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Drugs - Real World Outcomes is Scopus-indexed (Q3, CiteScore 3.9), WoS ESCI, DOAJ. Published by Adis.
Checked against the index lists dated .
ISSN 2198-9788Verify ISSN ↗2199-1154Verify ISSN ↗
Publisher: Adis
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacology (medical) | 140 / 278 | 49th | Q3 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2014–present, best quartile Q3, CiteScore 3.9.
Drugs - Real World Outcomes is Q3 in Pharmacology (medical) (rank 140 of 278), by CiteScore 2025.
Drugs - Real World Outcomes is indexed in the Emerging Sources Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 3.9, which places it in quartile Q3 at the 49th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.662, quartile Q2, with an H-index of 27.
The publisher lists an article processing charge of about US$3,090 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Drugs - Real World Outcomes is published by Adis. Its print ISSN is 2198-9788 and its online ISSN is 2199-1154.
Yes — indexed in the Emerging Sources Citation Index.
Yes — it is an open-access journal, listed in DOAJ.
Drugs - Real World Outcomes has an h-index of 33 and a 2-year mean of 2.42 citations per paper (OpenAlex). Its Scopus CiteScore is 3.9, quartile Q3. On 2-year citations it ranks #103 of 271 Scopus journals in Pharmacology (medical).
Drugs - Real World Outcomes published 61 papers in 2025; its busiest recent year was 2024 with 63. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 98 research articles (2025–2026), authors are most often from United States (18.9%), Japan (12.8%) and India (11.8%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.